Australian biotechnology company focused on nano-structured silicon drug delivery technologies including BioSilicon and BrachySil for oncology and other applications. Had operations in Australia, UK and US; listed on ASX and NASDAQ before restructuring to pSivida Corp. and rebranding as EyePoint Pharmaceuticals.
Also known as pSivida Corp., pSivida Corporation, PSD, and pSiMedica.
